TIKOSYN (dofetilide) and Authorized Generic (Dofetilide Capsules)

TREATMENT GUIDELINES

These guidelines are part of the TIKOSYN and Authorized Generic Risk Evaluation and Mitigation Strategy (REMS) Program for Tikosyn and its authorized generic, Dofetilide Capsules. Prescribers and Pharmacists are required to read these guidelines and sign a Certification Form acknowledging they understand the potential risks of TIKOSYN and its authorized generic in order to prescribe and dispense TIKOSYN and its authorized generic.
Below, you will find detailed treatment guidelines for TIKOSYN® and its authorized generic. Please call 1-877-TIKOSYN if you need additional information for Tikosyn and 1-800-447-3360 for Dofetilide Capsules.

Table of Contents

Important Safety Information ........................................ Page 3
Dosing Overview .......................................................... Page 4
Steps for Initiation and Dosing ....................................... Page 5
  • Predose Steps ......................................................... Page 5
  • Dosing ................................................................. Page 6
  • Postdose Adjustments ............................................... Page 7
  • Actions Prior to Patient Discharge .......................... Page 8
Patient Counseling ....................................................... Page 9

The product information in this document is intended for residents of the United States only.
Important Safety Information

TIKOSYN and its authorized generic are indicated for the conversion and maintenance of normal sinus rhythm (delay in the time to recurrence of atrial fibrillation/atrial flutter) in highly symptomatic patients with atrial fibrillation/atrial flutter of greater than 1 week.

TIKOSYN and its authorized generic are contraindicated:

- In patients with a known hypersensitivity to the drug
- In patients with congenital or acquired long QT syndromes (baseline QT interval or corrected QT [QTc] interval greater than 440 msec or 500 msec in patients with ventricular conduction abnormalities)
- In patients with severe renal impairment (calculated creatinine clearance <20 mL/min)
- With verapamil
- With hydrochlorothiazide (alone or in combination such as with triamterene)
- With cation transport inhibitors such as cimetidine*, ketoconazole, trimethoprim (alone or in combination with sulfamethoxazole), prochlorperazine, megestrol, and dolutegravir

*Alternatives to cimetidine include Maalox®, Prilosec®, and Zantac®

Warnings/Interactions: Inhibitors of CYP3A4 or renal cation transport, drugs that prolong the QT interval, and other antiarrhythmics may increase the risk of proarrhythmia either by increasing dofetilide exposure or by adding to its QT-prolonging effect.

Precautions/Interactions: The following should be coadministered with care as they might increase dofetilide levels: macrolide antibiotics, azole antifungal agents, protease inhibitors, selective serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, nefazodone, zafirlukast, norfloxacin, quinine, triamterene, metformin, amiloride, and grapefruit juice.

To minimize the risk of induced arrhythmia, patients initiated or re-initiated on TIKOSYN and its authorized generic should be placed for a minimum of 3 days in a facility that can provide calculations of creatinine clearance, continuous electrocardiographic monitoring, and cardiac resuscitation. TIKOSYN and its authorized generic are available only to hospitals and prescribers who have received appropriate TIKOSYN and its authorized generic dosing and treatment initiation education.
Dosing Overview

Please review this overview of dosing for TIKOSYN® and its authorized generic.

Dosing Algorithm Used in the TIKOSYN and its Authorized Generic Clinical Program

Place Patient on Telemetry

Check Baseline QTc

If QTc >440 msec, DO NOT Use dofetilide
If QTc ≤440 msec, Proceed

Calculated Creatinine Clearance (Clcr)

Male Clcr = (140-age) x actual body weight in kg
72 x serum creatinine (mg/dL)
Female Clcr = 0.85 x male

If Clcr is <20 mL/min, dofetilide is CONTRAINDICATED

If Clcr is >60 mL/min, give 500 mcg dofetilide BID
If Clcr is = 40-60 mL/min, give 250 mcg dofetilide BID
If Clcr is = 20-<40 mL/min, give 125 mcg dofetilide BID

Post Dose Adjustment:
2-3 hours after dose
Check QTc

(first dose only)
If Increase in QTc is ≤ 15%, Continue Current Dose

(first dose only)
If Increase in QTc is >15%, or >500 msec, Decrease Dose (see text)

If at any time after the second dose QTc increases >500 msec, dofetilide should be discontinued

The product information in this document is intended for residents of the United States only.
Steps for Initiation and Dosing

The following are suggested guidelines for the initiation and dosing of TIKOSYN® and its authorized generic:

**PREDOSE STEPS**

1. Before initiating TIKOSYN or its authorized generic therapy, previous antiarrhythmic therapy should be withdrawn for a minimum of 3 plasma half-lives. TIKOSYN and its authorized generic should not be initiated following amiodarone therapy until amiodarone plasma levels are below 0.3 mcg/mL or until amiodarone has been withdrawn for at least 3 months

2. Patients with atrial fibrillation should be anticoagulated according to usual medical practice

3. Admit patient to the telemetry unit; choose a telemetry lead with a visible QT interval. All measurements of the QT interval should be from this lead

4. Telemetry monitoring should continue for a minimum of 3 days or for 12 hours after conversion to normal sinus rhythm, whichever is longer

5. The concomitant use of verapamil, hydrochlorothiazide (alone or in combination, such as with triamterene), or the cation transport system inhibitors cimetidine, trimethoprim (alone or in combination with sulfamethoxazole), and ketoconazole with TIKOSYN and its authorized generic is contraindicated, as each drug causes a substantial increase in dofetilide plasma concentration. In addition, other known inhibitors of the renal cation transport system, such as prochlorperazine, dolutegravir and megestrol, should not be used in patients on TIKOSYN or its authorized generic. Please see full prescribing information for TIKOSYN and its authorized generic

6. **CAUTION** should be used when coadministering TIKOSYN or its authorized generic with macrolide antibiotics, azole antifungals, protease inhibitors, SRIs, amiodarone, cannabinoids, diltiazem, nefazodone, norfloxacin, quinine, zafirlukast, triamterene, metformin, amiloride, and grapefruit juice, as these agents may increase blood levels of TIKOSYN and its authorized generic

7. Concomitant administration of TIKOSYN or its authorized generic and digoxin is permitted. Carefully monitor patients for the signs and symptoms of digoxin toxicity. The concomitant administration of digoxin was associated with a higher occurrence of Torsade de Pointes. It is not clear whether this represents an interaction with TIKOSYN and its authorized generic or the presence of more severe structural heart disease in patients taking digoxin

8. If potassium (K+) is <4.0 mEq/L, replace K+ before administration of TIKOSYN or its authorized generic.
9. Before administering the first dose of TIKOSYN or its authorized generic on Day 1, measure the QTc interval (determine the QT if the heart rate is <60 bpm).
   - If baseline QTc is >440 msec (500 msec in patients with ventricular conduction abnormalities), TIKOSYN and its authorized generic are CONTRAINDICATED; if ~440 msec, you may proceed
   - Note time, date, and the telemetry lead on the strip
   - All measurements of the QTc interval should be from this lead

10. Measure the QT interval (determine QTc) 2-3 hours after each dose of TIKOSYN and its authorized generic until the patient is discharged.

11. Determine the patient’s actual body weight in kg.

12. Measure patient’s serum creatinine level as mg/dL.

13. Calculate patient’s creatinine clearance using the following formula:

   Male creatinine clearance = \((140\text{-age}) \times \text{actual body weight in kg}\)
   \[72 \times \text{serum creatinine (mg/dL)}\]

   Female creatinine clearance = \((140\text{-age}) \times \text{actual body weight in kg} \times 0.85\)
   \[72 \times \text{serum creatinine (mg/dL)}\]

**DOSING**

14. The creatinine clearance results should be received by the pharmacy to dispense the first TIKOSYN® or its authorized generic dose.

15. If the calculated creatinine clearance is <20 mL/min, TIKOSYN and its authorized generic is CONTRAINDICATED.

16. If the calculated creatinine clearance is >60 mL/min, the appropriate dose of TIKOSYN and its authorized generic is 500 mcg BID.
   - 2–3 hours after the initial dose, if QTc increases to >15% from baseline, then decrease TIKOSYN or its authorized generic to 250 mcg BID

17. If the calculated creatinine clearance is between 40 mL/min and 60 mL/min, the appropriate dose of TIKOSYN and its authorized generic is 250 mcg BID.
   - 2–3 hours after the initial dose, if QTc increases to >15% from baseline, then decrease TIKOSYN or its authorized generic to 125 mcg BID.
- If QTc increases to >500 msec (550 msec in the presence of a ventricular conduction abnormality), TIKOSYN or its authorized generic should be decreased to 125 mcg BID.

18. If the calculated creatinine clearance is 20 mL/min to <40 mL/min, the appropriate dose of TIKOSYN and its authorized generic is 125 mcg BID.

- >2–3 hours after the initial dose, if QTc increases to >15% from baseline, then decrease TIKOSYN or its authorized generic to 125 mcg QD.

- If QTc increases to >500 msec (550 msec in the presence of a ventricular conduction abnormality), then decrease TIKOSYN or its authorized generic to 125 mcg QD.

POSTDOSE ADJUSTMENTS

19. The second dose of TIKOSYN or its authorized generic should only be given after the QT has been determined. Only 1 down titration of TIKOSYN or its authorized generic for QTc is suggested. If QTc is still excessively prolonged, DISCONTINUE TIKOSYN or its authorized generic therapy.

20. During therapy initiation in the hospital, at 2-3 hours after each dose of TIKOSYN or its authorized generic, determine the QTc to see if dose adjustment is necessary.

- Response to QT measurement after the first dose:
  - If QTc increases by >15% or is >500 msec (550 msec in the presence of a ventricular conduction abnormality), decrease the TIKOSYN® or its authorized generic dose as described above

- Response to QT measurement after subsequent doses:
  - If after subsequent doses the QTc is >500 msec (550 msec in the presence of a ventricular conduction abnormality), TIKOSYN and its authorized generic should be DISCONTINUED

21. TIKOSYN and its authorized generic should be given q12h (actual times may vary according to local hospital practice; the doses should be given at the same time each day, i.e., 12 hours apart); QD TIKOSYN and its authorized generic should be given at the same time every day. The risk of Torsade de Pointes is related to dose as well as to patient characteristics. Physicians may, therefore, in some cases, choose doses lower than determined by the algorithm. If at any time this lower dose is increased, the patient needs to be rehospitalized for 3 days. Previous toleration of higher doses does not eliminate the need for rehospitalization.

22. After the third TIKOSYN or its authorized generic dose, discuss with patient the option of filling Rx with patient’s mail-order or retail pharmacy. Both the mail-order and retail pharmacy must be enrolled in the Tikosyn and Authorized Generic REMS Program. The physician who orders a TIKOSYN or its authorized generic prescription must be a

The product information in this document is intended for residents of the United States only.
confirmed participant of the TIKOSYN and Authorized Generic REMS Program. You will need the patient’s final dose of TIKOSYN or its authorized generic, patient’s full name (correct spelling), address, insurer, and physician’s name. If the TIKOSYN or its authorized generic dose is changed or discontinued after the prescription has been faxed, please notify the mail-order or retail pharmacy immediately.

Tikosyn and Authorized Generic In Pharmacy Systems (T.I.P.S™) Program Brochure describes the steps needed to enroll, order and dispense Tikosyn and its authorized generic for retail pharmacies. Please visit www.TIKOSYNREMS.com for enrollment information.

23. Contact your hospital pharmacy to order a TIKOSYN or its authorized generic bottle with 14 capsules of the final dosage strength.* The patient should be discharged with this bottle to ensure a sufficient drug supply for uninterrupted dosing until the patient receives the first outpatient supply of medication. Patient will be directed to fill prescription as soon as possible, since pharmacy may not have TIKOSYN or its authorized generic stocked and requires at least 24 hours to fill prescription.

*This bottle is supplied free of charge to hospitals.

**ACTIONS PRIOR TO PATIENT DISCHARGE**

24. Ensure the patient received the TIKOSYN or its authorized generic discharge bottle with 14 capsules.


26. Alert patients that blood work and electrocardiogram (ECG) will be re-evaluated every 3 months by their doctor to check the renal function and the QTc.

- If QTc exceeds 500 msec (550 msec in patients with ventricular conduction abnormalities), TIKOSYN and its authorized generic therapy should be discontinued and patients should be carefully monitored until QTc returns to baseline levels. If renal function deteriorates, adjust dose as described in steps 16-18 under “Dosing Overview.”

27. Inform the patient’s Healthcare Professional that the patient is now on TIKOSYN® or its authorized generic. Important points to mention include:

- TIKOSYN and its authorized generic are contraindicated with verapamil, hydrochlorothiazide (alone or in combination, such as with triamterene), and cation transport inhibitors such as cimetidine, ketoconazole, trimethoprim (alone or in combination with sulfamethoxazole), prochlorperazine, megestrol and dolutegravir.

- Renal function and QTc should be re-evaluated every 3 months or as medically warranted.

The product information in this document is intended for residents of the United States only.
• TIKOSYN and its authorized generic is available through a mail-order or retail pharmacy enrolled in the Tikosyn and Authorized Generic REMS Program. If the Healthcare Professional would like to write a refill for the patient, he or she must be a confirmed participant in the TIKOSYN and Authorized Generic REMS Program before the mail-order or retail pharmacy can fill the prescription. The Healthcare Professional can learn how to do this by calling 1-866-249-7261. Alternatively, the Healthcare Professional can continue to see the patient in consultation with a physician who is a confirmed participant in the TIKOSYN and Authorized Generic REMS Program.

• On receipt of patient information, the Healthcare Professional should read the enclosed package insert for more information. The most serious side effect of TIKOSYN and its authorized generic is Torsade de Pointes. The most common side effects with TIKOSYN and its authorized generic occurred at rates similar to placebo and included headache, chest pain, and dizziness.

**Patient Counseling**

28. Advise your patients to:

• Read the Medication Guide every time they receive their prescription, including refills

• Not take cimetidine, verapamil, ketoconazole, trimethoprim/sulfamethoxazole, hydrochlorothiazide, prochlorperazine, megestrol, or dolutegravir

• Tell you of all medications they are taking including prescription, non-prescription, natural/herbal remedies, and vitamins or dietary supplements

• Report symptoms associated with electrolyte imbalance, including excessive or prolonged diarrhea, sweating, vomiting, or loss of appetite or thirst

• Not miss doses or take extra doses of TIKOSYN or its authorized generic

• Not start any other medications, including OTCs without first consulting their doctor

• Get prescriptions filled and refilled as soon as possible to avoid any disruptions in treatment

• Report any adverse events

TIKOSYN and its authorized generic are indicated for the conversion to and maintenance of normal sinus rhythm (delay in the time to recurrence of atrial fibrillation/atrial flutter) in highly symptomatic patients with atrial fibrillation/atrial flutter of greater than 1 week.

To minimize the risk of induced arrhythmia, patients initiated, or re-initiated on TIKOSYN or its authorized generic should be placed for a minimum of 3 days in a

The product information in this document is intended for residents of the United States only.
facility that can provide calculations of creatinine clearance, continuous electrocardiographic monitoring, and cardiac resuscitation. TIKOSYN and its authorized generic are available only to hospitals and prescribers who have received appropriate TIKOSYN and its authorized generic dosing and treatment initiation education.

For full prescribing information, please visit www.TIKOSYNREMS.com.